FBR Capital Positive on Geron (GERN) After Not-So-Surprising Orphan Drug Designation for Imetelstat for MDS
Tweet Send to a Friend
FBR Capital analyst Thomas Yip reiterated an Outperform rating and $6 price target on Geron Corporation (NASDAQ: GERN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
